Clinical Trials Directory

Trials / Completed

CompletedNCT02293785

GREAT - Good Response With Appropriate Treatment

GREAT (Good Response With Appropriate Treatment) "Factors Influencing the Analgesic Response Over Time of the Oxycodone-Naloxone Association in Painful Cancer Patients"

Status
Completed
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
Mario Negri Institute for Pharmacological Research · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The symptoms associated in advanced cancer patients and adverse events due to use of opioids have major influence on the state of health and quality of life of patients. The pain, in particular, is a symptom with severe negative impact and with a prevalence ranging between 33% and 64%, according to the stage of the disease, with values around 70-90% in advanced stages and metastatic. The use of opioids, however, is usually associated with the appearance of common adverse events as drowsiness/sedation, constipation, nausea/vomiting, and dizziness. Some effects are self-limiting in the time for the appearance of tolerance while others, as constipation persist. Several clinical studies have demonstrated that the association oxycodone-naloxone (OXN), which consists in the union between a molecule agonist and an antagonist of opioid receptors, reduced the constipation in the presence of unchanged analgesic efficacy compared to oxycodone alone.

Conditions

Interventions

TypeNameDescription
DRUGOxycodone-Naloxone

Timeline

Start date
2014-11-01
Primary completion
2016-02-01
Completion
2016-02-01
First posted
2014-11-18
Last updated
2016-03-21

Locations

18 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT02293785. Inclusion in this directory is not an endorsement.